Ratings by Wells Fargo (Eva Fortea Verdejo)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Equal Weight (Overweight) |
88.49 (123.43) |
39.48% | Details | |
| 6/3/2026 | Celcuity Inc | CELC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2026 | Celcuity Inc | CELC | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2026 | LeMaitre Vascular | LMAT | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/4/2026 | Celcuity Inc | CELC | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/29/2026 | Kiniksa | KNSA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2026 | Revolution | RVMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/14/2026 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/30/2026 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
96.66 (88.49) |
-8.45% | Details | |
| 3/17/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2026 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Equal Weight (N/A) |
2.71 (3.70) |
36.53% | Details | |
| 3/2/2026 | Genmab A/S | GMAB | New Coverage | Overweight (N/A) |
29.44 (25.27) |
-14.16% | Details | |
| 2/27/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2026 | Kiniksa | KNSA | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/12/2025 | Kiniksa | KNSA | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/12/2025 | Relay Therapeutics | RLAY | Upgrade | Overweight (Equal Weight) |
7.79 (15.88) |
103.85% | Details | |
| 11/11/2025 | Bicara Therapeutics Inc | BCAX | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 9/29/2025 | Merus N.V. | MRUS | Downgrade | Equal Weight (Overweight) |
68.89 (90.00) |
30.64% | Details | |
| 9/25/2025 | Kiniksa | KNSA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/20/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Relay Therapeutics | RLAY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/7/2025 | iTeos Therapeutics | ITOS | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/6/2025 | Merus N.V. | MRUS | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/29/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2025 | Ideaya Biosciences | IDYA | New Coverage | Overweight (N/A) |
21.78 (31.23) |
43.39% | Details | |
| 5/28/2025 | iTeos Therapeutics | ITOS | Downgrade | Equal Weight (Overweight) |
8.53 (10.15) |
18.99% | Details | |
| 5/27/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/23/2025 | Bicara Therapeutics Inc | BCAX | Upgrade | Equal Weight (Underweight) |
15.66 (23.23) |
48.34% | Details | |
| 5/8/2025 | Merus N.V. | MRUS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/7/2025 | Merus N.V. | MRUS | New Coverage | Overweight (N/A) |
41.66 (68.89) |
65.36% | Details | |
| 5/3/2024 | Kiniksa | KNSA | New Coverage | Overweight (N/A) |
19.38 (55.11) |
184.37% | Details |
